|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Acorda Therapeutics Inc., of Hawthorne, N.Y., reached agreement with the FDA on a special protocol assessment for a second Phase III trial of Fampridine-SR in multiple sclerosis. The primary objective of the study is to show consistent improvements in walking for drug-treated patients. The design of MS-F204 is similar to Acorda's first Phase III trial of Fampridine-SR in MS, the successful MS-F203 study. However, the current study protocol will require 14 weeks of patient participation compared to 21 weeks in MS-F203. The FDA agreed the two trials would be adequate to support a new drug application filing. The new study is being planned. Fampridine-SR is a ...
Related newspaper, magazine, and journal articles:
|
|
Article: SINGAPORE'S PENGUIN BOAT INT'L ANNOUNCES 3 SE ASIAN ...
AsiaPulse News;
January 24, 2001 ;
569 words
...SINGAPORE, Jan 24 Asia Pulse - Penguin Boat International Limited has announced new ventures in Indonesia, Malaysia and Dili, East Timor. Its new subsidiary in Indonesia, P. T. Penguin Ferry Jasa, will have an issued and paid up capital of US$400,000, of which 95% will be held directly by Penguin,
|
|